VEGFA and hepatocellular carcinoma: Meanwhile, immune and stromal cell targeting strategies based on VEGF inhibition and program death-ligand 1 (PD-L1) blockade have shown unprecedented results7–9, being the first treatment regimen with improved overall survival relative to Sorafenib, a decade-long mainstay treatment for advanced-stage HCC patients10,11.